Cyclophilin A Prevents HIV-1 Restriction in Lymphocytes by Blocking Human TRIM5α Binding to the Viral Core.

Adult Antiviral Restriction Factors CD4-Positive T-Lymphocytes / drug effects Capsid / metabolism Cell Line Cyclophilin A / metabolism Cyclosporine / pharmacology HIV Infections / metabolism HIV-1 / drug effects Humans Lymphocytes / drug effects Mutation / genetics Protein Binding / drug effects Reverse Transcription / drug effects Tripartite Motif Proteins / metabolism Ubiquitin-Protein Ligases / metabolism
CD4(+) T cells CypA HIV-1 TRIM5α(hu) capsid core cyclosporine A restriction reverse transcription uncoating

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
17 03 2020
Historique:
received: 11 10 2019
revised: 23 12 2019
accepted: 26 02 2020
entrez: 19 3 2020
pubmed: 19 3 2020
medline: 24 3 2021
Statut: ppublish

Résumé

Disruption of cyclophilin A (CypA)-capsid interactions affects HIV-1 replication in human lymphocytes. To understand this mechanism, we utilize human Jurkat cells, peripheral blood mononuclear cells (PBMCs), and CD4

Identifiants

DOI: 10.1016/j.celrep.2020.02.100 PMID: 32187548 PMC: PMC7363000
pubmed: 32187548
pii: S2211-1247(20)30274-6
doi: 10.1016/j.celrep.2020.02.100
pmc: PMC7363000
mid: NIHMS1578469
pii:
doi:

Substances chimiques

Antiviral Restriction Factors 0
Tripartite Motif Proteins 0
Cyclosporine 83HN0GTJ6D
TRIM5 protein, human EC 2.3.2.27
Ubiquitin-Protein Ligases EC 2.3.2.27
Cyclophilin A EC 5.2.1.-

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3766-3777.e6

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI165236
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI150455
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007618
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI087390
Pays : United States
Organisme : NIGMS NIH HHS
ID : P50 GM082250
Pays : United States
Organisme : NIAID NIH HHS
ID : P50 AI150476
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI117943
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007501
Pays : United States
Organisme : NIAID NIH HHS
ID : K22 AI136691
Pays : United States
Organisme : NIGMS NIH HHS
ID : R25 GM086262
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI150998
Pays : United States

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests The authors declare no competing interests.

Références

Nature. 2004 Jul 29;430(6999):569-73
pubmed: 15243629
Nat Microbiol. 2019 Nov;4(11):1840-1850
pubmed: 31611641
Cell Host Microbe. 2010 Mar 18;7(3):221-33
pubmed: 20227665
Cell Host Microbe. 2008 Nov 13;4(5):495-504
pubmed: 18976975
PLoS Pathog. 2017 Aug 21;13(8):e1006570
pubmed: 28827840
J Virol. 2018 Sep 12;92(19):
pubmed: 29997211
Curr Biol. 2005 Jan 11;15(1):73-8
pubmed: 15649369
Virology. 2006 Jul 20;351(1):112-20
pubmed: 16643975
PLoS Pathog. 2014 Feb 20;10(2):e1003969
pubmed: 24586169
Cell. 1996 Dec 27;87(7):1285-94
pubmed: 8980234
Virology. 2006 Aug 1;351(2):404-19
pubmed: 16650449
J Virol. 1996 Jun;70(6):3551-60
pubmed: 8648689
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):534-9
pubmed: 21187419
Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14849-53
pubmed: 16203999
PLoS Pathog. 2013;9(10):e1003693
pubmed: 24130490
Blood. 1988 Dec;72(6):1904-10
pubmed: 2904290
Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3569-74
pubmed: 18287033
Elife. 2018 Dec 06;7:
pubmed: 30520725
J Virol. 2005 Jan;79(1):176-83
pubmed: 15596813
J Virol. 2009 Oct;83(20):10737-51
pubmed: 19656869
Nat Microbiol. 2019 Jun;4(6):933-940
pubmed: 30886358
Nat Microbiol. 2019 Dec;4(12):2044-2051
pubmed: 31636416
Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5514-9
pubmed: 16540544
Cell Rep. 2016 Oct 25;17(5):1438-1452
pubmed: 27783955
Cell. 2007 Oct 5;131(1):17-9
pubmed: 17923081
PLoS One. 2012;7(9):e46037
pubmed: 23049930
J Virol. 2012 May;86(10):5931-6
pubmed: 22398280
PLoS One. 2017 Aug 2;12(8):e0182298
pubmed: 28767697
Science. 2008 Feb 15;319(5865):921-6
pubmed: 18187620
Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1758-63
pubmed: 9465090
J Virol. 2006 May;80(10):4683-90
pubmed: 16641261
Nat Med. 2003 Sep;9(9):1138-43
pubmed: 12897779
J Virol. 2010 Jan;84(1):397-406
pubmed: 19846519
J Virol. 2007 Mar;81(5):2138-48
pubmed: 17135314
Virology. 2008 Sep 1;378(2):233-42
pubmed: 18586294
Nucleus. 2010 Sep-Oct;1(5):422-31
pubmed: 21326825
Retrovirology. 2011 Jan 30;8:7
pubmed: 21276267
Nat Protoc. 2019 Jan;14(1):1-27
pubmed: 30559373
J Virol. 2006 Jul;80(14):6738-44
pubmed: 16809279
Virology. 2008 Sep 30;379(2):335-41
pubmed: 18678385
J Virol. 2009 Nov;83(21):10951-62
pubmed: 19656870
Nat Med. 2001 May;7(5):631-4
pubmed: 11329067
J Virol. 2011 Aug;85(15):7818-27
pubmed: 21593146
Virology. 2013 May 25;440(1):8-18
pubmed: 23523133
PLoS Pathog. 2011 Mar;7(3):e1001313
pubmed: 21423673
Methods Mol Biol. 2009;485:55-72
pubmed: 19020818
PLoS Pathog. 2008 Feb 29;4(2):e1000003
pubmed: 18389077
J Biol Chem. 2011 Aug 12;286(32):27959-70
pubmed: 21680743
PLoS Pathog. 2011 Dec;7(12):e1002439
pubmed: 22174692
Cell. 1993 Jun 18;73(6):1067-78
pubmed: 8513493
J Virol. 2011 Sep;85(17):8725-37
pubmed: 21734049
Cell. 2008 Oct 3;135(1):49-60
pubmed: 18854154
Cell. 2009 Jun 26;137(7):1282-92
pubmed: 19523676
Gene Ther. 2010 Jul;17(7):859-71
pubmed: 20357830
J Virol. 2004 Dec;78(23):12800-8
pubmed: 15542632
EMBO J. 2001 Mar 15;20(6):1300-9
pubmed: 11250896
J Virol. 1998 Aug;72(8):6430-6
pubmed: 9658084
Virology. 2018 Oct;523:1-5
pubmed: 30056211
J Biol Chem. 2017 Dec 15;292(50):20494-20508
pubmed: 28974576
Curr Biol. 2008 Aug 26;18(16):1192-202
pubmed: 18722123
Nature. 1994 Nov 24;372(6504):363-5
pubmed: 7969495
Antimicrob Agents Chemother. 2008 Apr;52(4):1302-17
pubmed: 18212100

Auteurs

Anastasia Selyutina (A)

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Mirjana Persaud (M)

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Lacy M Simons (LM)

Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.

Angel Bulnes-Ramos (A)

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Cindy Buffone (C)

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Alicia Martinez-Lopez (A)

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Viviana Scoca (V)

Molecular Virology and Vaccinology Unit, CNRS UMR 3569, Department of Virology, Institut Pasteur, Paris, France.

Francesca Di Nunzio (F)

Molecular Virology and Vaccinology Unit, CNRS UMR 3569, Department of Virology, Institut Pasteur, Paris, France.

Joseph Hiatt (J)

Department of Cellular and Molecular Pharmacology, Quantitative Biosciences Institute, QBI, University of California, San Francisco, San Francisco, CA 94158, USA; J. David Gladstone Institutes, San Francisco, CA 94158, USA.

Alexander Marson (A)

Department of Medicine and Department of Microbiology and Immunology, Diabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA; Innovative Genomics Institute, University of California, Berkeley, CA 94720, USA; Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.

Nevan J Krogan (NJ)

Department of Cellular and Molecular Pharmacology, Quantitative Biosciences Institute, QBI, University of California, San Francisco, San Francisco, CA 94158, USA; J. David Gladstone Institutes, San Francisco, CA 94158, USA.

Judd F Hultquist (JF)

Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.

Felipe Diaz-Griffero (F)

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA. Electronic address: felipe.diaz-griffero@einstein.yu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Cyclophilin A Prevents HIV-1 Restriction in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de restriction antiviraux › Cyclophilin A Prevents HIV-1 Restriction in...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD4+ › Cyclophilin A Prevents HIV-1 Restriction in...
questionsmedicales.fr › Structures virales › Virion › Nucléocapside › Capside › Cyclophilin A Prevents HIV-1 Restriction in...
questionsmedicales.fr › Cellules › Cellules cultivées › Lignée cellulaire › Cyclophilin A Prevents HIV-1 Restriction in...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Isomerases › Cis-trans-isomerases › Peptidylpropyl isomerase › Cyclophiline A › Cyclophilin A Prevents HIV-1 Restriction in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Peptides cycliques › Cyclosporines › Ciclosporine › Cyclophilin A Prevents HIV-1 Restriction in...
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › Cyclophilin A Prevents HIV-1 Restriction in...
questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Lentivirus › Lentivirus des primates › VIH (Virus de l'Immunodéficience Humaine) › VIH-1 (Virus de l'Immunodéficience Humaine de type 1) › Cyclophilin A Prevents HIV-1 Restriction in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Cyclophilin A Prevents HIV-1 Restriction in...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Cyclophilin A Prevents HIV-1 Restriction in...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Cyclophilin A Prevents HIV-1 Restriction in...
questionsmedicales.fr › Métabolisme › Liaison aux protéines › Cyclophilin A Prevents HIV-1 Restriction in...
questionsmedicales.fr › Phénomènes génétiques › Expression des gènes › Transcription génétique › Transcription inverse › Cyclophilin A Prevents HIV-1 Restriction in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines à motif tripartite › Cyclophilin A Prevents HIV-1 Restriction in...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Ligases › Ubiquitin-protein ligase complexes › Ubiquitin-protein ligases › Cyclophilin A Prevents HIV-1 Restriction in...